收藏切换
Analysis of the Rationality and Safety of Clinical Application of PD-1 Anti-tumor Drugs Before and After Clinical Pharmacist Intervention
收藏切换
Zhongshun OUa, Xuemin LIUb, *, Mingjian CHENGa, Qingshang ZHANGa, Bang CAIb, Xiaofeng ZHUa
Pharmacy Today | 2026, 36(5) : 376 - 381
Less
收藏切换
Pharmacy Today | 2026, 36(5): 376-381
Analysis of the Rationality and Safety of Clinical Application of PD-1 Anti-tumor Drugs Before and After Clinical Pharmacist Intervention
Full
Zhongshun OUa, Xuemin LIUb, *, Mingjian CHENGa, Qingshang ZHANGa, Bang CAIb, Xiaofeng ZHUa
Affiliations
  • a.Department of Pharmacy, Yunfu, Guangdong 527300, China
  • b.Oncology Department, Yunfu People's Hospital, Yunfu, Guangdong 527300, China
Published: 2026-05-25 doi: 10.12048/j.issn.1674-229X.2026.05.009
Outline
收藏切换
OBJECTIVE

To analyze the rationality and safety of clinical use of PD-1 inhibitors as novel antitumor drugs, providing guidance for their standardized and safe clinical application.

METHODS

This study randomly selected inpatient medical records from April to June 2024 (before clinical pharmacist intervention) as the control group, and records from July 2024 to June 2025 (after intervention) as the intervention group. The rationality and safety of PD-1 inhibitor use were analyzed, with each 3-month period constituting a cycle. Results from each cycle were compared with those of the preceding cycle. Statistical analysis was performed to compare the rationality and safety of PD-1 inhibitor use between the first, second, third, and fourth intervention cycles and the pre-intervention cycle.

RESULTS

Post-intervention improvements were observed in prescription qualified rate, proportion of off-label use rate, and number of adverse drug reaction reports for PD-1 inhibitors. For prescription compliance and expanded clinical use indicators, the differences between the first, second, third, and fourth intervention cycles versus the pre-intervention cycle showed statistical significance (P<0.05).

CONCLUSION

Clinical pharmacist intervention enhances the rationality and standardization of PD-1 inhibitor use in clinical practice, facilitates timely identification of new or severe adverse reactions, and enables appropriate treatment measures, thereby reducing patient mortality, prolonging survival time, and reducing patients'medical costs.

clinical pharmacist  /  intervention  /  PD-1 inhibitors  /  rationality  /  safety
欧忠顺, 刘学敏, 成明建, 张庆尚, 蔡邦, 祝小凤. 临床药师干预前后对PD-1类抗肿瘤药物临床应用合理性与安全性分析. 今日药学, 2026 , 36 (5) : 376 -381 . DOI: 10.12048/j.issn.1674-229X.2026.05.009
Zhongshun OU, Xuemin LIU, Mingjian CHENG, Qingshang ZHANG, Bang CAI, Xiaofeng ZHU. Analysis of the Rationality and Safety of Clinical Application of PD-1 Anti-tumor Drugs Before and After Clinical Pharmacist Intervention[J]. Pharmacy Today, 2026 , 36 (5) : 376 -381 . DOI: 10.12048/j.issn.1674-229X.2026.05.009
Year 2026 volume 36 Issue 5
139
38
Cite this Article
BibTeX
Article Info
doi: 10.12048/j.issn.1674-229X.2026.05.009
  • Receive Date:2026-03-09
  • Online Date:2026-09-23
  • Published:2026-05-25
Article Data
Affiliations
History
  • Received:2026-03-09
Funding
Affiliations
    a.Department of Pharmacy, Yunfu, Guangdong 527300, China
    b.Oncology Department, Yunfu People's Hospital, Yunfu, Guangdong 527300, China
References
Share
https://castjournals.cast.org.cn/joweb/jryx/EN/10.12048/j.issn.1674-229X.2026.05.009
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT